A Recursive Partitioning Analysis Demonstrating Risk Subsets for 8-Year Biochemical Relapse After Margin-Positive Radical Prostatectomy Without Adjuvant Hormone or Radiation Therapy

Blute, 2001, Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy, J Urol, 165, 119, 10.1097/00005392-200101000-00030 Swindle, 2005, Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens, J Urol, 174, 903, 10.1097/01.ju.0000169475.00949.78 Kang, 2014, Concern for overtreatment using the AUA/ASTRO guideline on adjuvant radiotherapy after radical prostatectomy, BMC Urol, 14, 30, 10.1186/1471-2490-14-30 Ploussard, 2011, Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naive patients, BJU Int, 107, 1748, 10.1111/j.1464-410X.2010.09728.x Blute, 1997, Anatomic site-specific positive margins in organ-confined prostate cancer and its impact on outcome after radical prostatectomy, Urology, 50, 733, 10.1016/S0090-4295(97)00450-0 Watkins, 2015, Margin involvement at prostatectomy for clinically localized prostate cancer: does a low-risk group exist, Pract Radiat Oncol, 5, e31, 10.1016/j.prro.2014.04.005 Thompson, 2009, Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: Long-term followup of a randomized clinical trial, J Urol, 181, 956, 10.1016/j.juro.2008.11.032 Bolla, 2012, Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: Long-term results of a randomised controlled trial (EORTC trial 22911), Lancet, 380, 2018, 10.1016/S0140-6736(12)61253-7 Wiegel, 2014, Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial, Eur Urol, 66, 243, 10.1016/j.eururo.2014.03.011 Ghia, 2010, Adjuvant radiotherapy use and patterns of care analysis for margin-positive prostate adenocarcinoma with extracapsular extension: Postprostatectomy adjuvant radiotherapy: A SEER analysis, Urology, 76, 1169, 10.1016/j.urology.2010.04.047 Hoffman, 2011, Recommendations for post-prostatectomy radiation therapy in the United States before and after the presentation of randomized trials, J Urol, 185, 116, 10.1016/j.juro.2010.08.086 Vale, 2019, Adjuvant or salvage radiotherapy for the treatment of localised prostate cancer? A prospectively planned aggregate data meta-analysis, Ann Oncol, 30, v883, 10.1093/annonc/mdz394.041 Parker, 2019, Timing of radiotherapy (RT) after radical prostatectomy (RP): First results from the RADICALS RT randomised controlled trial (RCT) [NCT00541047], Ann Oncol, 30, v883, 10.1093/annonc/mdz394.042 Parker, 2020, Timing of radiotherapy after radical prostatectomy (RADICALS-RT): A randomised, controlled phase 3 trial, Lancet, 396, 1413, 10.1016/S0140-6736(20)31553-1 Vale, 2020, Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: A prospectively planned systematic review and meta-analysis of aggregate data, Lancet, 396, 1422, 10.1016/S0140-6736(20)31952-8 Sargos, 2020, Deep Neural Networks outperform the CAPRA score in predicting biochemical recurrence after prostatectomy, Front Oncol, 10 Tendulkar, 2016, Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy, J Clin Oncol, 34, 3648, 10.1200/JCO.2016.67.9647 King, 2012, The timing of salvage radiotherapy after radical prostatectomy: A systematic review, Int J Radiat Oncol Biol Phys, 84, 104, 10.1016/j.ijrobp.2011.10.069 Stephenson, 2009, Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era, J Clin Oncol, 27, 4300, 10.1200/JCO.2008.18.2501 Ochiai, 2008, Natural history of biochemical progression after radical prostatectomy based on length of a positive margin, Urology, 71, 308, 10.1016/j.urology.2007.08.042 Servoll, 2014, The length of a positive surgical margin is of prognostic significance in patients with clinically localized prostate cancer treated with radical prostatectomy, Urol Int, 93, 289, 10.1159/000362342 Shikanov, 2009, Length of positive surgical margin after radical prostatectomy as a predictor of biochemical recurrence, J Urol, 182, 139, 10.1016/j.juro.2009.02.139 van Oort, 2010, The length of positive surgical margins correlates with biochemical recurrence after radical prostatectomy, Histopathology, 56, 464, 10.1111/j.1365-2559.2010.03497.x Stephenson, 2009, Location, extent and number of positive surgical margins do not improve accuracy of predicting prostate cancer recurrence after radical prostatectomy, J Urol, 182, 1357, 10.1016/j.juro.2009.06.046 Seyedin SN, Mott SL, Snow AN, Russo JK, Watkins J. The impact of prostate cancer (PC) margin extent (ME) at radical prostatectomy (RP) on biochemical relapse-free survival (bRFS). J Clin Oncol. 2018;36(6_suppl):83-83. Valicenti, 2013, Adjuvant and salvage radiation therapy after prostatectomy: American Society for Radiation Oncology/American Urological Association guidelines, Int J Radiat Oncol Biol Phys, 86, 822, 10.1016/j.ijrobp.2013.05.029 National Comprehensive Cancer Network, Prostate Cancer (Version 2.2020). Available at: www.nccn.org. Accessed September 16, 2021. Wiegel, 2009, Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95, J Clin Oncol, 27, 2924, 10.1200/JCO.2008.18.9563 Trabulsi, 2008, A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer, Urology, 72, 1298, 10.1016/j.urology.2008.05.057 Leibovich, 2000, Benefit of adjuvant radiation therapy for localized prostate cancer with a positive surgical margin, J Urol, 163, 1178, 10.1016/S0022-5347(05)67717-8 Gandaglia, 2017, Adjuvant and salvage radiotherapy after radical prostatectomy in prostate cancer patients, Eur Urol, 72, 689, 10.1016/j.eururo.2017.01.039 Jensen, 2017, Outcomes and toxicity of 313 prostate cancer patients receiving helical tomotherapy after radical prostatectomy, Adv Radiat Oncol, 2, 597, 10.1016/j.adro.2017.08.004 Ost, 2009, Adjuvant high-dose intensity-modulated radiotherapy after radical prostatectomy for prostate cancer: clinical results in 104 patients, Eur Urol, 56, 669, 10.1016/j.eururo.2009.05.041 Kalbasi, 2014, Low rates of adjuvant radiation in patients with nonmetastatic prostate cancer with high-risk pathologic features, Cancer, 120, 3089, 10.1002/cncr.28856 Daniels, 2016, Predictors and rate of adjuvant radiation therapy following radical prostatectomy: A report from the Prostate Cancer Registry, J Med Imaging Radiat Oncol, 60, 247, 10.1111/1754-9485.12407 Chapin, 2018, Positive margin length and highest Gleason grade of tumor at the margin predict for biochemical recurrence after radical prostatectomy in patients with organ-confined prostate cancer, Prostate Cancer Prostatic Dis, 21, 221, 10.1038/s41391-017-0019-4 Emerson, 2005, The influence of extent of surgical margin positivity on prostate specific antigen recurrence, J Clin Pathol, 58, 1028, 10.1136/jcp.2005.025882 Sooriakumaran, 2015, The impact of length and location of positive margins in predicting biochemical recurrence after robot-assisted radical prostatectomy with a minimum follow-up of 5 years, BJU Int, 115, 106, 10.1111/bju.12483 Punnen, 2014, Multi-institutional validation of the CAPRA-S score to predict disease recurrence and mortality after radical prostatectomy, Eur Urol, 65, 1171, 10.1016/j.eururo.2013.03.058 Marascio, 2020, Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy, Prostate Cancer Prostatic Dis, 23, 295, 10.1038/s41391-019-0185-7 Pantel, 2019, Liquid biopsy and minimal residual disease - latest advances and implications for cure, Nat Rev Clin Oncol, 16, 409, 10.1038/s41571-019-0187-3 Azad, 2019, Circulating tumor DNA analysis for detection of minimal residual disease after chemoradiotherapy for localized esophageal cancer, Gastroenterology, 158, 494, 10.1053/j.gastro.2019.10.039